With a growing emphasis on real-world evidence and decentralized trial solutions, companies strive to improve the efficiency and effectiveness of research processes. Medable, Inc. has emerged as a pivotal force in this landscape, distinguishing itself as one of the fastest-growing healthcare tech companies. By leveraging its state-of-the-art platform, Medable has been transforming the way clinical trials are conducted, integrating participant onboarding, trial management, and data reporting into a seamless and intuitive experience.
Medable seamlessly integrates participant onboarding, trial management, and data reporting to simplify complex research processes and enhance the quality of clinical studies. Its unified platform incorporates tools such as TeleVisit, remote scheduling, and signature management, streamlining study initiation and ensuring compliance.
The platform’s robust features—remote data collection, study notifications, participant reminders, and real-time reporting—empower researchers to maintain control and generate high-quality evidence efficiently. Medable’s impact is evident through its 13x return on investment for Phase III trials and its recognition as the top-rated decentralized clinical trial (DCT) platform, serving 14 of the top 20 pharmaceutical companies.
What sets Medable apart is its best-in-class user experience, informed by insights from DCT experts, patients, and sites. The platform’s intuitive design accommodates the complexities of modern research while remaining user-friendly. Medable’s cloud-agnostic solution, available in over 60 countries and 120 languages, features a single API for seamless integration and scalability.
Medable’s platform streamlines workflows and accelerates study start-up with features like Total Consent Management, simplifying onboarding through digital screening, consent processes, and integrated TeleVisit capabilities. This solution achieved 75% site adoption in a U.S. Renal Care study for a top ten pharma trial, proving its flexibility and efficiency, especially for the elderly renal care population.
A key component, eCOA+ (electronic Clinical Outcome Assessments), enables rapid, high-quality data collection using over 400 pre-validated instruments. This technology reduces the critical path for study start-up, provides real-time data capture, and supports research across 120 languages. With eCOA+, Medable achieved a 50% faster study build time, advancing patient care with enhanced inclusivity and accessibility.
Supported by 24/7 global customer care and compliant with regulations like FDA 21 CFR Part 11 and GDPR, Medable delivers a seamless experience for patients and clinical sites, reducing participation burden while ensuring compliance.
We’re not just improving clinical trials; we’re revolutionizing how the world discovers new therapies, ensuring patients everywhere can benefit from medical advancements faster. — Michelle Longmire, CEO & Co-Founder
Medable’s AI-powered infrastructure expands global trial access, enhances participant engagement, and delivers cleaner, more reliable data, reducing delivery timelines by up to 50% for more efficient and successful clinical trials.
For oncology, Medable’s patient-first approach enhances the trial experience by prioritizing patient comfort and safety, whether at home or onsite. Tools such as eConsent, TeleVisit, and a specialized eCOA Oncology library facilitate patient participation from anywhere, ensuring engagement and compliance. Real-time notifications and long-term follow-up through tokenization enable sponsors to closely monitor patient data, improve retention, and capture critical endpoints. Medable’s technology provides up to 90 times more frequent measurements during follow-up, significantly boosting data quality and patient outcomes.
In vaccine trials, Medable’s scalable solutions address the need for rapid study start-ups and high-volume patient engagement. With pre-built tools in the Core package deployable in as little as five weeks and customizable options through Flex, including sensors and advanced system integrations, Medable ensures timely and efficient research.
Supported by a global network of over 1 million participants, Medable’s platform is designed to scale and excel in TA-specific trials, driving successful clinical research outcomes across the healthcare spectrum.
Medable is redefining the clinical trial experience, making it more inclusive, efficient, and impactful for everyone involved. Together with its partners, Medable is not just shaping the future of research but ensuring that life-changing treatments reach those who need them most.